Novo Nordisk Rejoins British Pharmaceutical Industry Association After Suspension

Novo Nordisk has regained its membership in the Association of the British Pharmaceutical Industry (ABPI) following a two-year suspension. The pharmaceutical company had been temporarily removed from the industry body due to concerns regarding its adherence to ABPI’s code of conduct.

The reinstatement marks the end of a period during which Novo Nordisk faced scrutiny over compliance issues with the association’s ethical and professional standards. ABPI, which represents pharmaceutical companies operating in the UK, enforces strict guidelines aimed at ensuring responsible practices within the industry. Details surrounding the specific compliance concerns that led to Novo Nordisk’s suspension have not been disclosed publicly. However, its return to membership indicates that these matters have been addressed to ABPI’s satisfaction.

Date: 18 March, 2025

Newsflash | Powered by GeneOnline AI

Related posts:

Breakthrough in Sustainable Chemistry: Waste Converted into Pharmaceuticals Using Artificial Photosynthesis CHMP Announces Key Approvals and Updates in February 2025 Meeting Novo Nordisk Introduces Lower-Cost Wegovy via Direct-to-Patient Sales Platform Novo Nordisk Announces Price Reduction for Wegovy Weight Loss Drug Amid Growing Demand

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後